Quantum BioPharma signs Thermo Fisher unit to run Phase 2 Lucid-MS trial

Quantum BioPharma Ltd. announced on October 6, 2026 that it has entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302, known as Lucid-MS, for multiple sclerosis.¹ The company said the contract is an important milestone in the drug's clinical development and marks the start of formal study start-up activities, following FDA clearance to proceed with the Phase 2 trial.¹

The CRO involved, the PPD Clinical Research Business within Thermo Fisher, is described as a global contract research organization with experience in central nervous system and multiple sclerosis studies.¹ Under the agreement, Thermo Fisher will support Quantum BioPharma in implementing the Phase 2 trial, including study start-up activities and related clinical research services.¹

The trial design calls for a randomized, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of MS, examining clinical and radiological endpoints tied to disease progression and biology.¹

Lucid-MS is described in the release as an "investigational, first-in-class New Chemical Entity designed to provide neuroprotection through inhibition of demyelination."¹ The company said it is developing the drug as a potential treatment for multiple sclerosis with a focus on progressive forms, targeting protein arginine deiminase 2, an enzyme implicated in myelin degradation.¹ In earlier testing, preclinical models showed the compound could prevent and reverse measures of myelin degradation, according to the company.¹

Quantum BioPharma develops Lucid-MS through its wholly owned subsidiary, Lucid Psycheceuticals Inc.¹ The filing was signed by Chief Financial Officer Donal Carroll on October 6, 2026.